These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30186414)

  • 1. Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials.
    Zheng JN; Bi TD; Zhu LB; Liu LL
    Exp Ther Med; 2018 Sep; 16(3):1882-1890. PubMed ID: 30186414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppressive agents in the treatment of IgA nephropathy: A meta-analysis of clinical randomized controlled literature.
    Zheng J; Gong X; Wu Z
    Niger J Clin Pract; 2020 Apr; 23(4):437-449. PubMed ID: 32246648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis.
    Han S; Yao T; Lu Y; Chen M; Xu Y; Wang Y
    Front Pharmacol; 2020; 11():539545. PubMed ID: 33551793
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of Patients with IgA Nephropathy: Evaluation of the Safety and Efficacy of Mycophenolate Mofetil.
    Chen Z; Chen W; Zheng L; Xie Y; Yao K; Zhou T
    Curr Pharm Des; 2024; 30(30):2400-2409. PubMed ID: 38988169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis.
    Du B; Jia Y; Zhou W; Min X; Miao L; Cui W
    BMC Nephrol; 2017 Jul; 18(1):245. PubMed ID: 28724421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Off-Label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis.
    Feng L; Song X; Shi X; Qin M; Liang N; Li B; Zhang B; Qin J
    Am J Nephrol; 2024 Sep; ():1-13. PubMed ID: 39321787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: A network meta-analysis.
    Liu T; Wang Y; Mao H; Yang L; Zhan Y
    Medicine (Baltimore); 2021 Feb; 100(8):e24541. PubMed ID: 33663060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive agents versus steroids in the treatment of IgA nephropathy-induced proteinuria: A meta-analysis.
    Liu Y; Xiao J; Shi X; Hao G; Chen Q; Zhou J; Wei X
    Exp Ther Med; 2016 Jan; 11(1):49-56. PubMed ID: 26889216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.
    Mak A; Cheak AA; Tan JY; Su HC; Ho RC; Lau CS
    Rheumatology (Oxford); 2009 Aug; 48(8):944-52. PubMed ID: 19494179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis.
    Xu G; Tu W; Jiang D; Xu C
    Am J Nephrol; 2009; 29(5):362-7. PubMed ID: 18974636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled-dose versus fixed-dose mycophenolate mofetil for kidney transplant recipients: a systematic review and meta-analysis of randomized controlled trials.
    Wang X; Qin X; Wang Y; Huang Z; Li X; Zeng Q; Zeng H; Lu Y; Wang L; Lin T
    Transplantation; 2013 Aug; 96(4):361-7. PubMed ID: 23558507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.
    Henderson LK; Masson P; Craig JC; Roberts MA; Flanc RS; Strippoli GF; Webster AC
    Am J Kidney Dis; 2013 Jan; 61(1):74-87. PubMed ID: 23182601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment for lupus nephritis.
    Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH; Le WB; Chen N; Wang WM; Liu ZS; Liu D; Chen JH; Tian J; Fu P; Hu ZX; Zeng CH; Liang SS; Zhou ML; Zhang HT; Liu ZH
    Am J Kidney Dis; 2017 Jun; 69(6):788-795. PubMed ID: 28215945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review.
    Chen Y; Li Y; Yang S; Li Y; Liang M
    BMC Nephrol; 2014 Dec; 15():193. PubMed ID: 25475967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
    Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.